300463.SHE Maccura Biotechnology Co Ltd
- Market cap
- CNY 5.48B
- P/E
- -
- P/B
- 0.86x
- ROE
- 0.8%
- Dividend yield
- 1.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300463.SHE undervalued?
Graham numberThe Graham number of Maccura Biotechnology Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Maccura Biotechnology Co Ltd fundamental analysis
No fundamental analysis for Maccura Biotechnology Co Ltd yet.
Maccura Biotechnology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Maccura Biotechnology Co Ltd
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such as digital PCR and extraction systems, and PCR kits; urinalysis analyzer systems …
Full company profileMaccura Biotechnology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Maccura Biotechnology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.49B | 1.97B | 2.69B | 3.22B | 3.70B | 3.98B | 3.61B | 2.90B | 2.55B | 2.17B | 2.15B |
| Gross Profit | 802M | 1.05B | 1.37B | 1.63B | 1.91B | 2.24B | 1.90B | 1.51B | 1.38B | 1.28B | 1.23B |
| Operating Income | 402M | 508M | 598M | 696M | 990M | 1.21B | 817M | 331M | 170M | 54.8M | 111M |
| EBITDA | 449M | 604M | 756M | 915M | 1.23B | 1.46B | 1.07B | 627M | 582M | 291M | 43.8M |
| Net Income | 312M | 374M | 445M | 525M | 794M | 957M | 708M | 313M | 127M | -35.8M | 53.4M |
| EPS | 0.56 | 0.67 | 0.80 | 0.94 | 1.42 | 1.72 | 1.17 | 0.51 | 0.21 | -0.06 | 0.09 |
| Balance Sheet | |||||||||||
| Total Assets | 2.70B | 3.58B | 4.56B | 5.50B | 6.36B | 6.57B | 8.16B | 8.12B | 7.98B | 7.99B | 7.80B |
| Total Liabilities | 415M | 970M | 1.69B | 2.17B | 2.36B | 2.03B | 1.63B | 1.51B | 1.55B | 1.69B | 1.47B |
| Shareholders' Equity | 2.24B | 2.50B | 2.70B | 3.13B | 3.80B | 4.30B | 6.29B | 6.38B | 6.37B | 6.28B | 6.30B |
| Cash & Short-term Investments | 154M | 344M | 442M | 444M | 612M | 637M | 1.25B | 1.15B | 732M | 667M | 858M |
| Total Debt | 199M | 670M | 1.19B | 1.51B | 1.32B | 1.12B | 701M | 320M | 446M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 49.3M | 79.0M | 194M | 460M | 1.09B | 1.62B | 843M | 912M | 634M | 602M | - |
| Capital Expenditure | 389M | 462M | 530M | 505M | 501M | 602M | 988M | 878M | 963M | 749M | 465M |
| Free Cash Flow | -339M | -383M | -336M | -45.2M | 593M | 1.01B | -145M | 23.6M | -329M | -147M | 110M |
| Ratios | |||||||||||
| ROE | 13.9% | 15.0% | 16.5% | 16.8% | 20.9% | 22.3% | 11.3% | 4.9% | 2.0% | -0.6% | 0.8% |
| ROA | 11.6% | 10.4% | 9.8% | 9.6% | 12.5% | 14.6% | 8.7% | 3.9% | 1.6% | -0.4% | 0.7% |
| Net Profit Margin | 21.0% | 19.0% | 16.6% | 16.3% | 21.4% | 24.0% | 19.6% | 10.8% | 5.0% | -1.7% | 2.5% |
| Debt to Equity | 0.09x | 0.27x | 0.44x | 0.48x | 0.35x | 0.26x | 0.11x | 0.05x | 0.07x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Maccura Biotechnology Co Ltd dividends
- Dividend yield
- 1.53%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 28, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 83.7M | 0.14 | - |
| 2024 | CNY 115M | 0.19 | 90.8% |
| 2023 | CNY 245M | 0.40 | 78.3% |
| 2022 | CNY 287M | 0.47 | 40.5% |
| 2021 | CNY 238M | 0.43 | 24.9% |
| 2020 | CNY 105M | 0.19 | 13.3% |
| 2019 | CNY 89.3M | 0.16 | 17.0% |
| 2018 | CNY 123M | 0.22 | 27.6% |
| 2017 | CNY 77.0M | 0.14 | 20.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on Jun 8, 2016.
Who owns Maccura Biotechnology Co Ltd
- Insiders 36.96%
- Institutions 3.88%
- Public & others 59.16%
- Shares outstanding 605M
- Free float 370M
Maccura Biotechnology Co Ltd company profile
- Company name
- Maccura Biotechnology Co Ltd
- Ticker
- 300463.SHE
- ISIN
- CNE1000020H3
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 2,946
- Fiscal year end
- December
- Address
- No.1006, Qihuang Road, Chengdu, China, 610219
- Phone
- 86 28 6161 9999
- Website
- maccura.com
About Maccura Biotechnology Co Ltd
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such as digital PCR and extraction systems, and PCR kits; urinalysis analyzer systems and semi-automatic urine analyzers; and hemostasis solutions, including coagulation and semi-automatic coagulation analyzers. It also provides clinical chemistry products, such as glycohemoglobin and protein analyzer, biochemistry systems, and chemistry regents; blood group product solutions; and pathology solutions, such as a liquid-based cytology processing system technologies. In addition, the company offers Mike Smart Lab, a patient-centered medical laboratory system solution based on automation and digital intelligence. Maccura Biotechnology Co.Ltd was founded in 1994 and is headquartered in Chengdu, China.
Maccura Biotechnology Co Ltd management
10- Mr. Wu MingjianGM & Director · born 1977
- Ms. Shan YinChief Financial Officer · born 1981
- Mr. Ping YouAccounting Supervisor & Director · born 1983
- Mr. Xin LinSenior Director of the Human Resources Department · born 1991
- Mr. Deng Ming WangDirector and Chief Business Officer · born 1966
- Ms. Wei ShiSecretary & Chief Strategic Investment Officer · born 1975
- Ms. Ping YuSenior Director · born 1981
- Mr. Zhen WangProduction Director · born 1971
- Mr. Tengxiang LongDirector of R&D - Reagents · born 1982
- Mr. Weijia WangDirector of R&D - Instrumentation · born 1984